MetaCap

Cellectis S.A. ADR (CLLS)

NASDAQ: CLLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.9209-0.0789 (-7.89%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CLLS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$92.76M
EPS (TTM)
-$1.26
52-week range
0.881 – 5.45
Day range
0.9028 – 0.9957
Volume / Avg
52.63K / 115.00K
Beta
—

52-week range

$0.881$5.45

CLLS stock today

Cellectis S.A. (CLLS) closed at $0.9209 on Nov 20, down 7.89% (-$0.0789), versus the S&P 500's 3.70% decline. Trading was light, with 52.63K shares changing hands, about 46% of the average daily volume. At this level, CLLS sits near the bottom of its 52-week range of $0.881 to $5.45: 83.1% below the high, set on Dec 11, 2025 and 4.5% above the low.

CLLS is down 81.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 80.4%. Cellectis S.A. has posted a net loss over the last twelve months (EPS of -$1.26), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cellectis S.A.

Company profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC).

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Andre Choulika Ph.D.
Headquarters
Paris
Employees
224
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Cellectis S.A. generated $72.9 million in revenue, up 75.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Cellectis S.A. reported a net loss of $67.6 million, compared with a loss of $36.8 million a year earlier. Gross margin was 100.0% (flat year over year) and operating margin -45.3%.

Cellectis S.A. annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$72.95M$41.51M$755.00K$19.17M$30.35M
Growth+75.76%+5397.35%-96.06%-36.83%-40.56%
Net income$-67.59M$-36.76M$-101.06M$-106.14M$-114.20M
EPS (diluted)$-0.67$-0.41$-1.77$-2.33$-2.55

Analyst forecast

Forecast

Consensus (5 analysts)

buy

Avg. price target

$5.50+497.24%

  • Strong buy 0
  • Buy 2
  • Hold 2
  • Sell 0
  • Strong sell 1

Target range

Low $2.50High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$0.01 vs —

CLLS news

All CLLS news

Cellectis S.A. peers

Health Care sector
CLLS peer companies
CompanyPrice% ChgMarket capCompare
DERMJourney Medical Corporation3.30-7.04%$93.16Mvs CLLS
CATXPerspective Therapeutics Inc.0.7538-3.85%$91.03Mvs CLLS
NTHINeOnc Technologies Holdings Inc.3.15-9.48%$90.88Mvs CLLS
NRXPNRX Pharmaceuticals Inc.2.15-15.69%$95.31Mvs CLLS
PDSBPDS Biotechnology Corporation0.7774-3.70%$95.39Mvs CLLS
NBPNovaBridge Biosciences ADR0.83-5.66%$96.28Mvs CLLS
UNCYUnicycive Therapeutics Inc.3.35-5.10%$97.77Mvs CLLS
CPIXCumberland Pharmaceuticals Inc.5.84-7.30%$87.57Mvs CLLS

Indexes, lists and sector

Cellectis S.A. stock FAQ

What is Cellectis S.A.'s stock price today?

CLLS last traded at $0.9209 as of Nov 20, 4:00 PM EST, down 7.89% on the day. Prices are delayed at least 15 minutes.

Who is Cellectis S.A.'s CEO?

Dr. Andre Choulika Ph.D. is the chief executive officer of Cellectis S.A. ADR, which has about 224 employees.

What is the CLLS 52-week high?

The 52-week high for CLLS is $5.45 and the 52-week low is $0.881. The stock is currently 83.1% below its high.

Compare CLLS